Neurogene's book value per share for the quarter that ended in Dec. 2024 was $20.89.
During the past 12 months, Neurogene's average Book Value Per Share Growth Rate was 44.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
Neurogene's current price is $15.11. Its book value per share for the quarter that ended in Dec. 2024 was $20.89. Hence, today's PB Ratio of Neurogene is 0.72.
During the past 4 years, the highest P/B Ratio of Neurogene was 6.46. The lowest was 0.42. And the median was 2.24.
Neurogene Book Value per Share Historical Data
The historical data trend for Neurogene's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neurogene's Book Value per Share
For the Biotechnology subindustry, Neurogene's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurogene's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neurogene's PB Ratio distribution charts can be found below:
* The bar in red indicates where Neurogene's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Neurogene (NAS:NGNE) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Neurogene Book Value per Share Related Terms
Thank you for viewing the detailed overview of Neurogene's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NGNE has been successfully added to your 